Skip to main content
OpenTrials
Completed

NCT Number: NCT02586129

Clinical Trial of YH14755 in Subjects With Dyslipidemia and Type II Diabetes

Randomized, double-blind, active-controlled, multicenter phase 3 trial to evaluate the safety and efficacy of YH14755 in subjects with dyslipidemia and Type II Diabetes.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Dyslipidemia Diabetes Mellitus Diabetes Mellitus, Type 2 Dyslipidemias Endocrine System Diseases Glucose Metabolism Disorders Lipid Metabolism Disorders Metabolic Diseases Nutritional and Metabolic Diseases Type II Diabetes

Age range

19 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Seoul National Universitiy Bundang Hospital

Seongnam-si, Gyeonggi-do, 463-707, South Korea

About this study

This is a phase 3 trial to evaluate the safety and efficacy of YH14755 in subjects with dyslipidemia and Type II Diabetes.

In YH14755 treatment group, 88 subjects will be assigned and the subjects administer YH14755 for 16 weeks.

In Metformin treatment group, 88 subjects will be assigned and the subjects administer Metformin for 16 weeks.

In Rosuvastatin treatment group, 88 subjects will be assigned and the subjects administer Rosuvastatin for 16 weeks.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Signed Informed Consent
  • Subjects with Dyslipidemia and Type II Diabetes
  • 6.5% ≤ HbA1c level ≤ 9.0% and LDL-C level ≤ 250mg/dL(6.5 nmal/L) at screening
  • BMI ≤ 45kg/m2
  • Subjects who dose not administered diabetes treatment at least 4 weeks prior to screening visit.
  • 19 years later, men and women under the age of 75

Exclusion criteria

  • Pregnant women, nursing mothers or subject who does not agree to assigned contraception in the study
  • Subject with type I Diabetes
  • Subject with hypertension which does not controlled by treatment(have blood pressure > 160/110mmHg)
  • Have a known allergy to drugs
  • Have administered Cyclosporine
  • Have administered Obesity treatment within 12 weeks prior to screening visit
  • Participated in any other clinical trials within 30 days prior to the first administration
  • Subject who is judged to be ineligible by investigator

Treatment and study plan

YH14755

Drug

20/1500mg, QD

metformin

Drug

1500mg, QD

Rosuvastatin

Drug

20mg, QD

Primary outcomes

  1. Change in LDL Cholesterol

    Time frame: Change from baseline at 16 weeks

  2. Change in HbA1c

    Time frame: Change from baseline at 16 weeks

Sponsors and collaborators

Lead sponsor

Yuhan Corporation

Industry

Registry information

Official study title

Randomized, Double-blind, Active-controlled, Multicenter Phase 3 Trial to Evaluate the Safety and Efficacy of YH14755 in Subjects With Dyslipidemia and Type II Diabetes

Important dates

Study start
2015
Primary completion
2017
Study completion
2017
First posted
Oct 26, 2015
Registry last updated
Oct 3, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.